Erythema following imatinib mesylate
Oxalosis: an unusual cause of leucoerythroblastic anaemia
THE PATHOPHYSIOLOGY OF VARIANT CREUTZFELDT–JACOB DISEASE: THE HYPOTHESES BEHIND CONCERNS FOR BLOOD COMPONENTS AND PRODUCTS
GUIDELINES FOR THE USE OF PLATELET TRANSFUSIONS
Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia
Modelling a minimal residual disease-based treatment strategy in childhood acute lymphoblastic leukaemia
Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease
Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines
Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate
Expression profile of wild-type ETV6 in childhood acute leukaemia
Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation
Therapy-related myelodysplasia and/or acute myeloid leukaemia after autologous haematopoietic progenitor cell transplantation in a prospective single centre cohort of 221 patients
Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation
C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease
Use of a cDNA microarray to determine molecular mechanisms involved in grey platelet syndrome
The human granulocyte/macrophage colony-stimulating factor receptor [alpha]2 isoform influences haemopoietic lineage commitment and divergence
EVALUATION OF THROMBOPHYLIC STATES IN MYELOMA PATIENTS RECEIVING THALIDOMIDE: A REASONABLE DOUBT
USE OF THALIDOMIDE IN PATIENTS WITH MYELOMA AND RENAL FAILURE MAY BE ASSOCIATED WITH UNEXPLAINED HYPERKALAEMIA
SAFETY OF HIGH-DOSE LIPOSOMAL DAUNORUBICIN (DAUNOXOME) FOR REFRACTORY OR RELAPSED ACUTE MYELOBLASTIC LEUKAEMIA
HAVE URINARY LEVELS OF THE ANGIOGENIC FACTORS, BASIC FIBROBLAST GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR, A PROGNOSTIC VALUE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA?
RESPONSE TO ‘COMPARISON OF “SEQUENTIAL” VERSUS “STANDARD” CHEMOTHERAPY AS RE-INDUCTION TREATMENT, WITH OR WITHOUT CYCLOSPORINE, IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA (AML): RESULTS OF THE UK MEDICAL RESEARCH COUNCIL AML-R TRIAL’
HUMAN HERPESVIRUS 6 ENCEPHALITIS FOLLOWING FLAG CHEMOTHERAPY
Errata
Announcement